The news indicates that Morgan Stanley's stance on Exscientia remains unchanged, maintaining an Equal-Weight rating and a $14 price target. This suggests that the analyst believes the stock is fairly valued and does not expect significant short-term price movement. As a result, the short-term impact on Exscientia's stock price is neutral.